Interferon in the treatment of ill adults with Covid-19 in the Republic of Guinea

• Published in: African health sciences Vol. 23; no. 2; pp. 43 - 55
• Main Authors: Moya, Valentín Santiago Rodríguez, Águila, Ladys Alfonso, Camara, Nohuou Mangué, Cisse, Sékuo Ditinn, Mamady, Doukure, Keïta, Sakoba, Bakary, Kava Mamady, Pérez, Lianet Díaz, Casañas, Elaine Díaz
• Format: Journal Article
• Language: English
• Published: Uganda Makerere Medical School 01.06.2023
• Subjects: SARS-Cov-2; COVID 19; zoonosis; human recombinant interferon
• ISSN: 1680-6905; 1729-0503
• DOI: 10.4314/ahs.v23i2.6

Effective and safe antiviral treatments are required to refrain the COVID-19. Investigate the efficacy and safety of interferon in the treatment of COVID-19. The inclusion criteria were patients who gave their signed consent, with detection confirmed by RT-PCR of SARS-CoV-2, 18 years and older. Patients received therapy as per the Guinea COVID-19 protocol in the group B; the group A received the same treatment including administration of interferon. The outcome measures the time to negative conversion of SARS-CoV-2, mortality, patients transferred to ICU and safety, according to the reports of adverse events. 345 patients were included, 171 in the group A and 174 in the group B. After the treatments, the RT-PCR negative results were attained in the patients in the group A in 9.15±4.79 days and in those in the group B in 14.83±6.67 days. No patient in the group A had to be transferred to ICU, and they all survived; in the group B, 26 patients were transferred to ICU and six of them died. There were eight adverse events with causality relation with interferon administration. The interferon resulted effective and safe in contributing to the viral replication conversion to negative results in shorter time and to survival.